These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31549577)

  • 1. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
    Raman SV; Hor KN; Mazur W; Cardona A; He X; Halnon N; Markham L; Soslow JH; Puchalski MD; Auerbach SR; Truong U; Smart S; McCarthy B; Saeed IM; Statland JM; Kissel JT; Cripe LH
    J Am Heart Assoc; 2019 Oct; 8(19):e013501. PubMed ID: 31549577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial.
    Raman SV; Hor KN; Mazur W; He X; Kissel JT; Smart S; McCarthy B; Roble SL; Cripe LH
    Orphanet J Rare Dis; 2017 Feb; 12(1):39. PubMed ID: 28219442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
    Raman SV; Hor KN; Mazur W; Halnon NJ; Kissel JT; He X; Tran T; Smart S; McCarthy B; Taylor MD; Jefferies JL; Rafael-Fortney JA; Lowe J; Roble SL; Cripe LH
    Lancet Neurol; 2015 Feb; 14(2):153-61. PubMed ID: 25554404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left Ventricular Magnetic Resonance Imaging Strain Predicts the Onset of Duchenne Muscular Dystrophy-Associated Cardiomyopathy.
    Siddiqui S; Alsaied T; Henson SE; Gandhi J; Patel P; Khoury P; Villa C; Ryan TD; Wittekind SG; Lang SM; Taylor MD
    Circ Cardiovasc Imaging; 2020 Nov; 13(11):e011526. PubMed ID: 33190531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precordial R wave height does not correlate with echocardiographic findings in boys with Duchenne muscular dystrophy.
    Thrush PT; Edward N; Flanigan KM; Mendell JR; Allen HD
    Congenit Heart Dis; 2013; 8(6):561-7. PubMed ID: 23510265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.
    Silva MC; Magalhães TA; Meira ZM; Rassi CH; Andrade AC; Gutierrez PS; Azevedo CF; Gurgel-Giannetti J; Vainzof M; Zatz M; Kalil-Filho R; Rochitte CE
    JAMA Cardiol; 2017 Feb; 2(2):190-199. PubMed ID: 27926769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
    Hammer F; Malzahn U; Donhauser J; Betz C; Schneider MP; Grupp C; Pollak N; Störk S; Wanner C; Krane V;
    Kidney Int; 2019 Apr; 95(4):983-991. PubMed ID: 30712923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.
    Hor KN; Mazur W; Taylor MD; Al-Khalidi HR; Cripe LH; Jefferies JL; Raman SV; Chung ES; Kinnett KJ; Williams K; Gottliebson WM; Benson DW
    J Cardiovasc Magn Reson; 2011 Oct; 13(1):60. PubMed ID: 22011358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure.
    Kobayashi M; Yamashina A; Satomi K; Tezuka A; Ito S; Asakura M; Kitakaze M; Ferreira JP
    Int J Cardiol; 2024 Nov; 415():132477. PubMed ID: 39181408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy.
    Leung M; Wong VW; Heritier S; Mihailidou AS; Leung DY
    Cardiovasc Diabetol; 2013 Oct; 12():139. PubMed ID: 24083804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Sudano I; Naegele M; Roas S; Périat D; Frank M; Kouroedov A; Noll G; Lüscher TF; Enseleit F; Ruschitzka F; Flammer AJ
    Clin Cardiol; 2016 May; 39(5):285-90. PubMed ID: 26991772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise Cardiac Magnetic Resonance Imaging in Boys With Duchenne Muscular Dystrophy Without Cardiac Disease.
    Power LC; Gusso S; Hornung TS; Jefferies C; Derraik JGB; Hofman PL; O'Grady GL
    Pediatr Neurol; 2021 Apr; 117():35-43. PubMed ID: 33662889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial application of three-dimensional speckle-tracking echocardiography to detect subclinical left ventricular dysfunction and stratify cardiomyopathy associated with Duchenne muscular dystrophy in children.
    Yu HK; Xia B; Liu X; Han C; Chen W; Li Z
    Int J Cardiovasc Imaging; 2019 Jan; 35(1):67-76. PubMed ID: 30105418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.